PURPOSE: To determine whether quadrivalent HPV vaccination is effective in reducing recurrent disease in women with a previous history of HPV disease. METHODS:All women under 45 years of age treated for HPV-linked disease and with negative HPV test, cytology and colposcopy 3 months after treatment were enrolled. Women were randomly assigned into two groups: a group that received HPV vaccine post treatment and a group that was only submitted to follow-up. Follow-up was performed every 6 months for a duration of at least 3 years. Kaplan-Meier curve was used to estimate the overall disease-free survival during the follow-up period. Statistical analysis was performed by Fisher's exact test. RESULTS:From November 2013 to October 2014, we enrolled a total of 178 women at Careggi University Hospital in Florence and at Azienda USL in Massa Carrara. 12 out of 89 patients in the non-vaccination group recurred (13.5%), while 3 out of 89 patients in the vaccination group recurred (3.4%). The Kaplan-Meier curves showed a statistically difference in the log rank test (p = 0.0147) for the overall disease-free survival in the study groups during follow-up. The rate of recurrence was significantly higher in the non-vaccination group, with a p = 0.0279 by Fisher exact test. CONCLUSION: The introduction of anti-HPV vaccination during the follow-up post treatment for HPV-linked disease is recommended to reduce the risk of recurrence. The clinical implication of this could be very important to influence post-treatment management of HPV disease.
RCT Entities:
PURPOSE: To determine whether quadrivalent HPV vaccination is effective in reducing recurrent disease in women with a previous history of HPV disease. METHODS: All women under 45 years of age treated for HPV-linked disease and with negative HPV test, cytology and colposcopy 3 months after treatment were enrolled. Women were randomly assigned into two groups: a group that received HPV vaccine post treatment and a group that was only submitted to follow-up. Follow-up was performed every 6 months for a duration of at least 3 years. Kaplan-Meier curve was used to estimate the overall disease-free survival during the follow-up period. Statistical analysis was performed by Fisher's exact test. RESULTS: From November 2013 to October 2014, we enrolled a total of 178 women at Careggi University Hospital in Florence and at Azienda USL in Massa Carrara. 12 out of 89 patients in the non-vaccination group recurred (13.5%), while 3 out of 89 patients in the vaccination group recurred (3.4%). The Kaplan-Meier curves showed a statistically difference in the log rank test (p = 0.0147) for the overall disease-free survival in the study groups during follow-up. The rate of recurrence was significantly higher in the non-vaccination group, with a p = 0.0279 by Fisher exact test. CONCLUSION: The introduction of anti-HPV vaccination during the follow-up post treatment for HPV-linked disease is recommended to reduce the risk of recurrence. The clinical implication of this could be very important to influence post-treatment management of HPV disease.
Authors: Violante Di Donato; Giuseppe Caruso; Marco Petrillo; Evangelos Kontopantelis; Innocenza Palaia; Giorgia Perniola; Francesco Plotti; Roberto Angioli; Ludovico Muzii; Pierluigi Benedetti Panici; Giorgio Bogani Journal: Vaccines (Basel) Date: 2021-04-21
Authors: Violante Di Donato; Giuseppe Caruso; Giorgio Bogani; Eugenio Nelson Cavallari; Gaspare Palaia; Giorgia Perniola; Massimo Ralli; Sara Sorrenti; Umberto Romeo; Angelina Pernazza; Alessandra Pierangeli; Ilaria Clementi; Andrea Mingoli; Andrea Cassoni; Federica Tanzi; Ilaria Cuccu; Nadia Recine; Pasquale Mancino; Marco de Vincentiis; Valentino Valentini; Gabriella d'Ettorre; Carlo Della Rocca; Claudio Maria Mastroianni; Guido Antonelli; Antonella Polimeni; Ludovico Muzii; Innocenza Palaia Journal: Vaccines (Basel) Date: 2022-02-04
Authors: Konstantinos S Kechagias; Ilkka Kalliala; Sarah J Bowden; Antonios Athanasiou; Maria Paraskevaidi; Evangelos Paraskevaidis; Joakim Dillner; Pekka Nieminen; Bjorn Strander; Peter Sasieni; Areti Angeliki Veroniki; Maria Kyrgiou Journal: BMJ Date: 2022-08-03
Authors: Anna Acampora; Adriano Grossi; Andrea Barbara; Vittoria Colamesta; Francesco Andrea Causio; Giovanna Elisa Calabrò; Stefania Boccia; Chiara de Waure Journal: Int J Environ Res Public Health Date: 2020-10-30 Impact factor: 3.390
Authors: Ana Paula Costa; Paulo César Giraldo; Ricardo Ney Cobucci; Márcia Lopes Consolaro; Raquel Pantarotto Souza; Luanda Barbara Canário; Paula Renata Machado; Rand Randall Martins; Pedro Vieira Baptista; José Eleutério Jr; Ana Katherine Gonçalves Journal: Asian Pac J Cancer Prev Date: 2020-09-01